ArticleCancer chemotherapy and pharmacology2025
Benefit of plasma cystatin C for carboplatin individual dosing in a patient with spinal amyotrophy.
Article in Cancer chemotherapy and pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCarboplatin is used in several chemotherapy regimens and is mainly excreted by kidneys. The recommended dose is calculated using a target exposure (area under the curve or AUC) and a predicted carboplatin clearance (CLcarbo). This clearance could be obtained by equations based on the estimation of glomerular filtration rate (GFR) including serum creatinine (SCr) alone or with plasma Cystatin C (CysC). CASE PRESENTATION: A 68-years-old woman with uterine carcinosarcoma and lymph node/lung metastases should be treated by carboplatin-paclitaxel. However, her SCr level was extremely low (i.e., 10 µmol/L) due to a spinal amyotrophy. Therefore, carboplatin clearance and dose calculation was estimated from an equation based on CysC, body weight, and age but not SCr proposed by Thomas et al. A therapeutic drug monitoring was performed to determine the patient’s actual CLcarbo.
resultsThe patient presented an actual CLcarbo close to the value predicted by the equation based on CysC (93.7 and 92.8 mL/min, respectively). The other formulae based on SCr alone or with CysC would have been associated with a substantial overestimation of her CLcarbo and thus would have led to drug overexposure.
conclusionWe concluded that the Thomas equation based on CysC alone represents a suitable alternative in patients with very low serum creatinine concentration due to amyotrophy.
Indexed as
Identifiers
41379234What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.